IDEAYA Biosciences, Inc. $IDYA Stake Lifted by Candriam S.C.A.

Candriam S.C.A. raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 7.4% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,107,708 shares of the company’s stock after buying an additional 76,354 shares during the quarter. Candriam S.C.A.’s holdings in IDEAYA Biosciences were worth $36,909,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. GSK plc bought a new stake in IDEAYA Biosciences in the 4th quarter valued at about $46,093,000. Baker BROS. Advisors LP increased its stake in shares of IDEAYA Biosciences by 54.6% in the third quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock valued at $89,125,000 after purchasing an additional 1,156,716 shares during the period. State Street Corp increased its stake in shares of IDEAYA Biosciences by 27.6% in the fourth quarter. State Street Corp now owns 4,134,641 shares of the company’s stock valued at $142,935,000 after purchasing an additional 893,707 shares during the period. Janus Henderson Group PLC raised its holdings in shares of IDEAYA Biosciences by 11.8% during the fourth quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company’s stock valued at $248,344,000 after buying an additional 758,117 shares during the last quarter. Finally, First Turn Management LLC acquired a new position in shares of IDEAYA Biosciences during the fourth quarter worth approximately $25,017,000. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Down 0.8%

IDEAYA Biosciences stock traded down $0.29 during midday trading on Friday, hitting $36.99. The company’s stock had a trading volume of 677,504 shares, compared to its average volume of 1,373,421. The stock’s 50-day moving average price is $31.50 and its 200-day moving average price is $32.63. IDEAYA Biosciences, Inc. has a 12 month low of $21.33 and a 12 month high of $40.58. The company has a market capitalization of $3.25 billion, a PE ratio of -23.12 and a beta of -0.09.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The firm had revenue of $6.56 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period last year, the business posted ($0.82) EPS. The company’s quarterly revenue was down 39.4% on a year-over-year basis. As a group, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -4.1 EPS for the current year.

Analyst Ratings Changes

IDYA has been the topic of several analyst reports. Royal Bank Of Canada lowered their target price on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a research report on Tuesday. Mizuho lowered their price target on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Citigroup reaffirmed a “market outperform” rating on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Wedbush reissued an “outperform” rating and set a $58.00 target price on shares of IDEAYA Biosciences in a research note on Friday, June 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a report on Friday, May 22nd. Fifteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and an average price target of $50.25.

Insiders Place Their Bets

In other IDEAYA Biosciences news, CAO Briseno Andres Ruiz sold 9,550 shares of IDEAYA Biosciences stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the transaction, the chief accounting officer owned 26,466 shares in the company, valued at approximately $1,058,904.66. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.